 | Humanigen, Inc.: Humanigen Terminates Exploration of Potential Rights Offering
www.finanznachrichten.de - December 2 at 9:35 AM |
 | Humanigen Terminates Exploration of Potential Rights Offering
finance.yahoo.com - December 2 at 9:35 AM |
| Humanigen to Present at the 2019 Stifel Healthcare Conference
finance.yahoo.com - November 15 at 1:29 PM |
| Humanigen Announces Two Abstracts Accepted at the 2019 Annual Meeting of the Society for Neuro-Oncology, including Oral Presentation on its Next Generation EphA3-CAR-T
finance.yahoo.com - November 12 at 1:01 PM |
| Humanigen Announces Two Lenzilumab Abstracts Accepted for Presentation at 2019 Annual Meeting of American Society of Hematology
finance.yahoo.com - November 6 at 1:28 PM |
 | Humanigen to explore potential rights offering
seekingalpha.com - October 15 at 9:22 AM |
| Humanigen Announces Exploration of Potential Rights Offering
finance.yahoo.com - October 15 at 9:22 AM |
| New ‘Blood Advances®’ Publication Supports Humanigen’s GM-CSF Neutralization Strategy with Lenzilumab in GvHD
finance.yahoo.com - October 8 at 12:24 PM |
| Humanigen in-licenses technology used to prevent GvHD
seekingalpha.com - July 22 at 6:55 PM |
| Humanigen Secures Exclusive Worldwide License for the Prevention of GvHD through GM-CSF Neutralization from the University of Zurich
finance.yahoo.com - July 22 at 9:10 AM |
| Humanigen Secures Exclusive Worldwide License to Gene-Editing Technology from Mayo Clinic to Improve CAR-T
finance.yahoo.com - July 2 at 8:59 AM |
| Humanigen to Present at the Jefferies 2019 Healthcare Conference
finance.yahoo.com - June 3 at 8:52 AM |
| Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
finance.yahoo.com - May 31 at 8:58 AM |
| Publication in blood® Highlights Potential for GM-CSF Neutralization as a Solution for CAR-T Induced Neurotoxicity
finance.yahoo.com - May 16 at 7:20 PM |
| Humanigen Announces Preliminary Results From Ifabotuzumab Phase I Study Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 1 at 9:04 AM |
| Humanigen Data Presented at the 2019 National Comprehensive Cancer Network (NCCN) Annual Conference Demonstrates Potential to Improve the Efficacy of CAR-T Therapy
finance.yahoo.com - March 21 at 7:06 PM |
| Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Accepted as Oral Presentation at the 2019 Transplantation & Cellular Therapy (TCT) Annual Meeting
finance.yahoo.com - February 25 at 9:31 AM |
 | Humanigen Inc
www.bloomberg.com - February 21 at 9:18 AM |
| Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Selected for Front Cover of Current Edition of ‘blood’®, The Official Journal of the American Society of Hematology (ASH)
finance.yahoo.com - February 15 at 9:07 AM |
| Humanigen Announces Publication Demonstrating EphA3 Receptor as an Attractive Antibody Target for Brain Cancer and Other Solid Tumor Therapy in the Journal ‘Cancers’
finance.yahoo.com - January 4 at 10:45 AM |
| Lenzilumab Data Presented in Oral Presentation at the American Society of Hematology (ASH)
finance.yahoo.com - December 4 at 8:56 AM |
| Lenzilumab Study Published in ‘blood’, the Official Journal of the American Society of Hematology (ASH), First Edition
finance.yahoo.com - November 30 at 9:22 AM |
| Humanigen Announces Lenzilumab Study Results Accepted as Oral Presentation at the 2018 Annual Meeting of the American Society of Hematology (ASH)
finance.yahoo.com - November 2 at 9:13 AM |
| Humanigen's lenzilumab shows encouraging action in preclinical study
seekingalpha.com - August 20 at 4:38 PM |
| Humanigen Announces Positive Topline Study Results
finance.yahoo.com - August 20 at 8:55 AM |
| Humanigen CEO to Present at 8th Annual LD Micro Invitational
finance.yahoo.com - May 30 at 8:56 AM |
| Lupagen & Humanigen to explore point-of-care CAR-T therapy
finance.yahoo.com - May 22 at 8:47 AM |
| Humanigen Announces Preclinical Findings Presented on Lenzilumab’s Potential to Optimize CAR-T Therapy
finance.yahoo.com - May 11 at 9:27 AM |
| Humanigen Names Dr. Tarek Sahmoud as Chief Medical Officer
finance.yahoo.com - April 30 at 8:59 AM |
| Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of KaloBios Pharmaceuticals, Inc. -- HGEN, formerly KBIO
finance.yahoo.com - April 19 at 8:50 AM |
| Humanigen Signs Agreement With MD Anderson Cancer Center to Begin Research Investigating Lenzilumab as CAR-T Support
finance.yahoo.com - April 16 at 8:48 AM |
| Humanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab for Treatment of Chronic Myelomonocytic Leukemia
finance.yahoo.com - March 15 at 8:48 AM |
| Humanigen Appoints Robert Savage to Board of Directors
finance.yahoo.com - March 12 at 12:05 PM |
| Humanigen CEO to Present at Inaugural LD Micro Virtual Conference
finance.yahoo.com - March 1 at 5:23 PM |
| Humanigen Completes Exchange of Loan Obligations for Equity
finance.yahoo.com - February 27 at 5:28 PM |
| Humanigen Appoints Rainer Boehm, M.D., to Board of Directors
finance.yahoo.com - February 7 at 9:40 AM |
| Humanigen CEO to Present at NobleCon14, BIO CEO Investor Conferences
finance.yahoo.com - January 25 at 9:33 AM |
| Humanigen Signs Definitive Agreements to Exchange Loan Obligations for Equity
finance.yahoo.com - December 22 at 9:53 AM |
| Humanigen Announces up to $15 Million Committed Equity Financing Facility
finance.yahoo.com - November 15 at 2:53 AM |
| Humanigen Appoints Chief Financial Officer
finance.yahoo.com - November 15 at 2:53 AM |
